Literature DB >> 19255292

Trends in hospitalizations for AIDS-associated Pneumocystis jirovecii Pneumonia in the United States (1986 to 2005).

Colleen F Kelley1, William Checkley2, David M Mannino3, Carlos Franco-Paredes1, Carlos Del Rio1, Fernando Holguin4.   

Abstract

BACKGROUND: Although hospitalizations for AIDS-associated Pneumocystis jirovecii pneumonia (PCP) in the United States have decreased since the introduction of chemoprophylaxis and potent combination antiretroviral therapy (ART), PCP remains an important cause of illness and death among AIDS patients.
METHODS: We analyzed trends in AIDS-associated PCP hospital discharges using the National Hospital Discharge Surveys between 1986 and 2005.
RESULTS: An estimated 539 million patients were discharged from hospitals between 1986 and 2005, of whom an estimated 312,411 had AIDS-associated PCP. The proportion of patients discharged from the hospital with AIDS-associated PCP decreased from 31% before the introduction of chemoprophylaxis (1986 to 1989) to 17% with chemoprophylaxis (1990 to 1995) and subsequently to 9% after the introduction of ART in 1996 (p < 0.001). Mortality from AIDS-associated PCP decreased from 21 to 16% and subsequently to 7% between these three time periods (p < 0.001). Among those who received mechanical ventilation, mortality decreased from 79% in the prechemoprophylaxis era to 31% in the ART era (p < 0.001) alongside an increase (from 5 to 11%) in the use of mechanical ventilation. We also observed a shift in the population at-risk for PCP over time: a greater proportion of black people, women, and people from Southern states were affected (all p < 0.001).
CONCLUSIONS: While there have been significant reductions in hospitalizations and hospital mortality for AIDS-associated PCP over the last 20 years, these reductions have not been homogenous across demographic subpopulations and geographic regions and point to new at-risk populations. Furthermore, mortality in severe cases of PCP that require mechanical ventilation has improved substantially.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19255292     DOI: 10.1378/chest.08-2859

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  27 in total

Review 1.  Histopathologic diagnosis of fungal infections in the 21st century.

Authors:  Jeannette Guarner; Mary E Brandt
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

2.  Outcomes for critically ill patients with HIV and severe sepsis in the era of highly active antiretroviral therapy.

Authors:  Jared A Greenberg; Jeffrey L Lennox; Greg S Martin
Journal:  J Crit Care       Date:  2011-10-26       Impact factor: 3.425

3.  Dectin immunoadhesins and pneumocystis pneumonia.

Authors:  David M Ricks; Kong Chen; Mingquan Zheng; Chad Steele; Jay K Kolls
Journal:  Infect Immun       Date:  2013-07-08       Impact factor: 3.441

Review 4.  Opportunistic yeast pathogens: reservoirs, virulence mechanisms, and therapeutic strategies.

Authors:  Elizabeth J Polvi; Xinliu Li; Teresa R O'Meara; Michelle D Leach; Leah E Cowen
Journal:  Cell Mol Life Sci       Date:  2015-02-21       Impact factor: 9.261

5.  A new method for the detection of Pneumocystis jirovecii using flow cytometry.

Authors:  J Barbosa; C Bragada; S Costa-de-Oliveira; E Ricardo; A G Rodrigues; C Pina-Vaz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-16       Impact factor: 3.267

Review 6.  Colonization by Pneumocystis jirovecii and its role in disease.

Authors:  Alison Morris; Karen A Norris
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

7.  Possible Diagnostic Delays and Missed Prevention Opportunities in Pneumocystis Pneumonia Patients Without HIV: Analysis of Commercial Insurance Claims Data-United States, 2011-2015.

Authors:  Jeremy A W Gold; Brendan R Jackson; Kaitlin Benedict
Journal:  Open Forum Infect Dis       Date:  2020-06-29       Impact factor: 3.835

8.  Predicting mortality from HIV-associated Pneumocystis pneumonia at illness presentation: an observational cohort study.

Authors:  M W Fei; E J Kim; C A Sant; L G Jarlsberg; J L Davis; A Swartzman; L Huang
Journal:  Thorax       Date:  2009-10-12       Impact factor: 9.139

9.  Cost-effectiveness analysis of diagnostic options for pneumocystis pneumonia (PCP).

Authors:  Julie R Harris; Barbara J Marston; Nalinee Sangrujee; Desiree DuPlessis; Benjamin Park
Journal:  PLoS One       Date:  2011-08-15       Impact factor: 3.240

10.  Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes.

Authors:  Yasufumi Matsumura; Yuichiro Shindo; Yoshitsugu Iinuma; Masaki Yamamoto; Michinori Shirano; Aki Matsushima; Miki Nagao; Yutaka Ito; Shunji Takakura; Yoshinori Hasegawa; Satoshi Ichiyama
Journal:  BMC Infect Dis       Date:  2011-03-25       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.